GLOBAL CHI BC (01757) has formally announced in Hong Kong its strategic move into the artificial intelligence anti-aging (AI anti-aging) field, aiming to drive technological upgrades in the health and wellness and medical aesthetics industries. The company plans to leverage its advantages as a listed platform to integrate AI, biological data, and clinical anti-aging technologies, establishing a comprehensive AI anti-aging system that covers skin quality monitoring, aging assessment, personalized solutions, and effect tracking. This strategic initiative involves deep collaboration with multiple high-quality industry partners, including Suki Yuanchuang—a joint venture between Hong Kong-listed medical aesthetics company Liangqing Holdings (08603), biotech firm MIRXES-B (02629), and Japanese pharmaceutical company NAGAWA—as well as Dipu Xingzhou, an AI scenario implementation service provider backed by the technical capabilities of Hong Kong-listed AI solutions provider Dipu Technology (01384). Liangqing Holdings will utilize its deep cooperation with NAGAWA and MIRXES-B to introduce top-tier clinical anti-aging detection technologies from Japan, complemented by Singapore-based MiRXES' world-leading clinical R&D infrastructure. Combined with AI technology synergies from GLOBAL CHI BC and Dipu Technology, this will promote the intelligent, scientific, and global upgrade of comprehensive anti-aging services, establishing a benchmark for high-end anti-aging services in the Asia-Pacific region. Dipu Xingzhou will utilize AI large models and multi-dimensional biological data modeling to provide core technical support for AI anti-aging, including the quantification of aging indicators, precise analysis of blood reports, and personalized ingredient and solution recommendations, enabling the quantification of aging metrics and tailored solution offerings. Currently, GLOBAL CHI BC operates securities and trust businesses in Hong Kong, while in mainland China, it focuses on the "major medical aesthetics and health" sector through its subsidiaries Wangchen Medical Technology Group and Tongfan Health Technology Group. The move into AI anti-aging represents a technological enhancement and scenario expansion based on existing operations. Additionally, the company recently plans to develop an integrated e-commerce platform that combines online transactions, smart supply chain management, and digital marketing services to build an online-to-offline ecosystem. Mr. Zhou Zhenlin, Chairman of GLOBAL CHI BC, stated that AI anti-aging is a key step in the company's diversified development strategy. The firm will collaborate with Suki Yuanchuang and Dipu Xingzhou and also intends to partner with international leaders such as Singaporean biotech companies and renowned Japanese pharmaceutical firms to advance a full-chain industrial layout integrating "AI technology + clinical anti-aging + biotech R&D + commercial operations." Moving forward, the company will continue to invest in technology R&D and market expansion, integrating global core anti-aging resources to create a highly recognizable AI anti-aging benchmark project in the Hong Kong stock market, delivering long-term value for shareholders and the market.